SSDT Meeting
Teleconference 23rd March, 2017 1530 CET

NAME	PARTNER
Eizirik (DE)	ULB
Cnop (MC)	ULB
Gloyn (AG)	UOXF
Ferrer (JF)	IDIBAPS
Torrents (DT)	BSC
Stabile-Barnett (CSB)	A2F
Renström (ER)	ULUND
Apologies	
Hansen (TH)	UCPH
Stumpf (MS)	ICL

Text in red represents actions arising from the meeting

1. Review and approval of previous minutes and actions arising

The minutes of the previous meeting were reviewed and approved by the partners. The actions arising from the minutes were noted and would be considered as part of the current meeting.

2. Overview of project progress.

MC provided an update on project progress across the work packages. She indicated that generally work was progressing and that there seemed to be confidence that the deliverables due at M18 of the project would be achieved.

With respect to Deliverable 2.1 concerning the development of tools it was noted that Intomics would lead this development. JF indicated that there were developments associated with the TIGER resource that can be used for this deliverable. He indicated that the Intomics analysis tools would be beneficial to include if it was possible.

DE indicated that Intomics were to be invited to attend the SSDT but were not present at this meeting. It was **agreed** to make contact with them again and invite them to participate in the SSDT.

DT suggested that there might be some restrictions on the inclusion of Intomics tools in the deliverable as they were of commercial value but some of their work on protein/protein interaction, already published, should be included.

It was noted that TH was not available to provide an update on Deliverable 5.5 and 5.6, but AG provided an overview of the collaboration that she was undertaking with TH group.
TH has also provided the following update by email before the SSDT:

We are analyzing re-sequencing data from >10k individuals of various genes known to be involved in monogenic diabetes. We find an excess of rare variants in several genes among >3k T2D patients compared to controls.

We are studying the impact of variants in hERG on incretin, glucagon and insulin secretion.
We have initiated the first pharmacogenetic study of adverse effects of statin treatment in diabetic patients.
Generation of the pipeline for retrieving pharma data from the Danish registers will allow us to do more focused studies on progression of diabetes estimated by increasing usage of OHA and insulin.

DT indicated that the deliverables that he was associated with should be fine. He noted that the publically available web access point for delivery in M36 should also be fine.

3. Update on consortium meeting in Barcelona

CSB gave an update on the numbers that would be attending the meeting in Barcelona. He indicated that the programme would be circulated together with travel information on Monday 27th March, 2017.

There was some discussion regarding the meeting and the following points were noted:

- MS would not attend the meeting but a representative would provide a presentation. It was **agreed** to speak with MS following the Barcelona meeting to ensure that progress was being maintained.
- AG suggested that flight details be requested from the participants so that people could arrange to share a taxi if appropriate. CSB **agreed** to request this information on 27th March.
- It was decided that a slot for a presentation from one of the ISAB members would be a good idea. MC **agreed** to contact Jose Florez to invite him for a 30 min lecture.

4. Deliverables and milestones

WP1. Creation of the TIGER repository

DT gave an update regarding WP1 indicating that progress with the development of TIGER was going well and that there was another TC on 7th April, 2017 and that it might be possible to provide some screen shots of progress during this TC. Building of the first interface is progressing well.

DT indicated that there were some issues that needed to be discussed at the consortium meeting in Barcelona. He would like to have a discussion for around 20 minutes on the points for consideration as part of WP1. MC **agreed**, and this will be included in the program.

WP2 Systems biology modelling
There was no update regarding the progress with the work package. It was decided to review progress at the consortium meeting in Barcelona.

WP3 Experimental validation and effects of metabolic perturbations and therapeutic interventions.

AG gave an update on the work that she was involved with. This included investigation of human islets from the Pisa group exposed to GLP1 analogues. These were currently being analysed. Studies investigating glucose and free fatty acid exposure were also progressing well.

MC suggested that it would be appropriate to discuss the possible interaction with the Rhapsody project at this point.

MC indicated that with respect to the two projects there were areas of significant potential overlap. One of these areas related to WP3 within the T2DSystems project. There was a proposal from the Rhapsody consortium to consider data sharing between the two projects. This could be beneficial as it would allow a level of co-ordination between the projects and possibly strengthen the size and quality of the data sets being shared.

MC proposed that in the first instance a teleconference was established between common partners and industrial members of the two projects to consider how data sharing might operate. MC proposed that this take place before the T2DSystems meeting in Barcelona so that discussion and a decision could be taken at that meeting.

MC indicated that the common partners between the two projects were:

- UPI
- ULB
- LUND
- UOXF

DT, DE and JF raised a concern as Rhapsody was an IMI involving SME's and large companies and thought that the sharing of data sets might be restricted due to the nature of the IMI.

AG suggested that it would be a good idea to explore the areas of overlap that exist and how the projects could collaborate in these areas. She indicated that it could be beneficial and with only a few centres providing human islets it could help prevent the same donor being counted twice.

DE indicated that he was in agreement with a discussion between Rhapsody and T2DSystems.

AG informed the members that she would like to see a discussion around the scientific work plan before seeking to establish any agreements.

JF reminded the group that within the TIGER resource each of the partners was responsible for their own data. They can agree to share data and have access to data generated by other partners.

DE and JF suggested that perhaps in the first instance the basis for collaboration would be:

- Agree a common identifier for samples
- As soon as data is published (or accepted for publication) it can be shared in both directions
- Keep an open channel for discussion regarding study collaboration, aiming to harmonize as much as possible experimental design for subsequent data sharing and pooling.

MC suggested that this would be a rather minimal collaboration and JF suggested that perhaps data could be shared once it was available within the TIGER resource of T2DSystems and vice versa.

DE proposed that the opening position for T2DSystems should be as mentioned above and then negotiate as required.

AG was supportive of this approach.

MC and AG indicated that they were keen to align the WP3 objectives between the two projects.

DT indicated his approval for such an approach to be made to Rhapsody.

JF raised the point as to whether it would be data sharing of primary or final data sets. This would need to be agreed. DT also re-affirmed that as Rhapsody was an IMI there might be restrictions on data sharing.

MC asked CSB to doodle poll availability of individuals for a teleconference during April but before the consortium meeting in Barcelona. CSB indicated that perhaps the data access committee members might be a good starting point. He **agreed** to send MC a list of candidates and then contact them for a teleconference.

WP4 In vivo beta cell pathophysiology

ER gave an update on progress with respect to the work package. He indicated that the data had been transferred to the TIGER system and that this had appeared to proceed without a problem.

He raised the recent email discussion regarding sequencing samples generated by Marchetti and confirmed that this would be possible at Malmo. However, he suggested that the consortium make a proposal for a budget to undertake the work and he could then determine if it was achievable.

He confirmed that Jonathan was making good progress towards the work package deliverables and that at the present time he did not see any difficulty in achieving the M24 and M48 deliverables.

DE asked if ER was engaged in collaboration with other partners and ER indicated that not much had taken place at the present time. He indicated that while the potential for collaboration with TH was likely, at the present time the main focus had been the TIGER resource.

There was some discussion concerning the sequencing question. There are approximately 140 samples from Marchetti and quotations of around €64k for sequencing had been suggested. T2DSystems doesn't have the budget identified to cover this cost but it would be very beneficial for the project. ER **agreed** to check how much it might cost for his group to undertake the sequencing within the next few days.

AG indicated that she was very supportive of the sequencing. At UOXF the price would be similar to that quoted for Imperial.

DE indicated that once a decision had been made it would be necessary to inform a.s.a.p. Marchetti (UPI) on how the sequencing would be managed and how it would be paid.

WP5 Stratified diagnosis and prevention

TH was not available for the meeting but he had provided a update by email (see above under item 2).

WP6 Management

CSB reminded the partners that the end of the first reporting period would be 30th June, 2017. He would give a presentation at the consortium meeting to address the activities that need to be undertaken as part of the reporting process.

AOB

There was discussion concerning the number of teleconferences for the project and CSB indicated that the SSDT had meetings every 2 months at the present time. The Dissemination and Exploitation Board would meet every 6 months. The TIGER development group would have the next teleconference on 7th April, 2017.

CSB suggested that perhaps the group should be expanded for the SSDT to include all work package leaders, Intomics, and Marchetti. This was **agreed.**

The meeting was closed.

The next SSDT teleconference is scheduled for **Thursday May 25th at 1300 BST (1400 CET)**